Daxor (DXR) Competitors $7.76 +0.16 (+2.11%) As of 03:18 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. PDEX, LUNG, ZJYL, PROF, LUCD, INFU, OBIO, ICAD, MGRM, and GUTSShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Pro-Dex (PDEX), Pulmonx (LUNG), Jin Medical International (ZJYL), Profound Medical (PROF), Lucid Diagnostics (LUCD), InfuSystem (INFU), Orchestra BioMed (OBIO), iCAD (ICAD), Monogram Orthopaedics (MGRM), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry. Daxor vs. Pro-Dex Pulmonx Jin Medical International Profound Medical Lucid Diagnostics InfuSystem Orchestra BioMed iCAD Monogram Orthopaedics Fractyl Health Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Which has more risk & volatility, DXR or PDEX? Daxor has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Do institutionals & insiders hold more shares of DXR or PDEX? 1.3% of Daxor shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 59.0% of Daxor shares are owned by company insiders. Comparatively, 47.5% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is DXR or PDEX more profitable? Pro-Dex has a net margin of 11.06% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 21.68% beat Daxor's return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A Pro-Dex 11.06%21.68%12.40% Does the MarketBeat Community believe in DXR or PDEX? Pro-Dex received 154 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 61.90% of users gave Pro-Dex an outperform vote. CompanyUnderperformOutperformDaxorOutperform Votes2100.00% Underperform VotesNo VotesPro-DexOutperform Votes15661.90% Underperform Votes9638.10% Which has higher earnings and valuation, DXR or PDEX? Pro-Dex has higher revenue and earnings than Daxor. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxor$2.13M17.25N/AN/AN/APro-Dex$64.12M2.31$2.13M$2.8016.22 Does the media prefer DXR or PDEX? In the previous week, Pro-Dex had 2 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Daxor. Pro-Dex's average media sentiment score of 1.42 beat Daxor's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media. Company Overall Sentiment Daxor Neutral Pro-Dex Positive Do analysts recommend DXR or PDEX? Daxor currently has a consensus target price of $25.00, indicating a potential upside of 228.95%. Pro-Dex has a consensus target price of $52.00, indicating a potential upside of 14.47%. Given Daxor's higher probable upside, analysts plainly believe Daxor is more favorable than Pro-Dex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pro-Dex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPro-Dex beats Daxor on 9 of the 13 factors compared between the two stocks. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.76M$4.53B$5.40B$8.49BDividend YieldN/A43.65%5.22%4.11%P/E RatioN/A29.8226.7119.93Price / Sales17.2570.77395.44119.84Price / CashN/A51.0838.2534.62Price / BookN/A6.316.854.59Net IncomeN/A$68.16M$3.23B$248.19M7 Day Performance4.11%21.03%5.35%2.21%1 Month Performance-4.76%25.54%13.31%16.23%1 Year Performance-21.49%22.21%17.58%8.00% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor3.8598 of 5 stars$7.76+2.1%$25.00+222.2%-21.5%$37.54M$2.13M0.0037PDEXPro-Dex2.6471 of 5 stars$42.49+5.5%$52.00+22.4%+130.9%$138.56M$64.12M21.14140News CoveragePositive NewsHigh Trading VolumeLUNGPulmonx3.5245 of 5 stars$3.32-9.8%$12.07+263.6%-62.4%$133.66M$87.47M-2.31250Positive NewsZJYLJin Medical InternationalN/A$0.85-5.7%N/A-74.2%$132.60M$23.50M0.00245PROFProfound Medical2.3139 of 5 stars$4.27-0.2%$11.50+169.3%-39.2%$128.33M$10.68M-3.19150LUCDLucid Diagnostics3.0297 of 5 stars$1.19+8.2%$3.50+194.1%+39.8%$125.41M$4.35M-1.0470High Trading VolumeINFUInfuSystem2.4633 of 5 stars$5.75+4.9%$13.00+126.1%N/A$120.84M$134.86M95.85410News CoveragePositive NewsHigh Trading VolumeOBIOOrchestra BioMed2.8577 of 5 stars$2.94+10.9%$14.20+383.0%-43.6%$112.64M$2.64M-1.834ICADiCAD0.4759 of 5 stars$3.93+5.9%N/A+141.5%$107.86M$19.61M-30.23140News CoverageAnalyst ForecastHigh Trading VolumeMGRMMonogram Orthopaedics3.266 of 5 stars$2.59-1.5%$5.40+108.5%+40.1%$91.40M$364,999.00-5.5128Earnings ReportGUTSFractyl Health1.7382 of 5 stars$1.77+3.5%$11.00+521.5%-69.9%$86.69M$93,000.00-0.15102 Related Companies and Tools Related Companies Pro-Dex Alternatives Pulmonx Alternatives Jin Medical International Alternatives Profound Medical Alternatives Lucid Diagnostics Alternatives InfuSystem Alternatives Orchestra BioMed Alternatives iCAD Alternatives Monogram Orthopaedics Alternatives Fractyl Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.